Related Experiment Video

Updated: Apr 28, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K

CYP4F2 genetic polymorphisms are associated with coronary heart disease in a Chinese population

Changqing Yu, Qingkai Yan, Chunjiang Fu

  • 1Department of Cardiology, Daping Hospital, The Third Military Medical University, 10#Changjiangzhilu, Yuzhong District, Chongqing 400042, People's Republic of China. wangxk_008@126.com.

Lipids in Health and Disease
|June 3, 2014
PubMed

Insights

Genetic variations in the CYP4F2 gene are linked to coronary heart disease (CHD) risk in the Chinese Han population. Specific single nucleotide polymorphisms (SNPs) and haplotypes influence susceptibility to CHD.

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Population Genetics

Background:

  • Coronary heart disease (CHD) poses a significant global health burden.
  • Investigating genetic factors, such as CYP4F2 gene polymorphisms, is crucial for understanding CHD etiology.
  • The Chinese Han population represents a distinct genetic demographic for such studies.

Purpose of the Study:

  • To investigate the association between CYP4F2 gene polymorphisms and the risk of coronary heart disease (CHD).
  • To analyze specific single nucleotide polymorphisms (SNPs) and haplotypes within the CYP4F2 gene.
  • To evaluate these genetic factors in a Chinese Han population.

Main Methods:

  • A case-control study design was employed with 440 CHD patients and 440 controls.
  • Genotyping of four CYP4F2 SNPs (rs2108622, rs3093100, rs3093105, rs3093135) was performed using PCR-RFLP.
  • Statistical analysis compared genotype and haplotype distributions between cases and controls.

Main Results:

  • Single nucleotide polymorphisms rs2108622 and rs3093105 in the CYP4F2 gene showed a significant association with CHD risk (P < 0.01).
  • Haplotype analysis revealed that the GGGT haplotype (rs2108622-rs3093100-rs3093105-rs3093135) was associated with an increased risk of CHD (OR = 4.367, P < 0.001).
  • Conversely, the GGTA haplotype was linked to a decreased risk of CHD (OR = 0.450, P < 0.001).

Conclusions:

  • CYP4F2 gene polymorphisms are significantly associated with the risk of developing coronary heart disease.
  • Specific CYP4F2 genotypes and haplotypes may serve as potential genetic markers for CHD susceptibility.
  • Further research is warranted to elucidate the functional mechanisms underlying these associations.
Abstract

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.3K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
337
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.5K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
137